Adaptogen Definition And Scientific Criteria

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

RD

By Gabriela Mitchell, Registered Dietitian (Linkedin)

Last Updated August 2026  ·  27 min read

10% off · weekly tips

Real science on cortisol, stress, and sleep.

Send it →

---

Table of Contents

1. What Is an Adaptogen? The Core Concept Explained
2. The History of the Adaptogen Concept: Brekhman's Framework
3. The Three Scientific Criteria Every Adaptogen Must Meet
4. Adaptogen Scientific Definition: How It Reads in the Literature
5. Adaptogen Classification: How Researchers Categorize These Substances
6. The Adaptogen Category in Regulatory and Official Contexts
7. Which Herbs Actually Meet the Adaptogen Requirements?
8. How Adaptogens Differ From Stimulants and Nootropics
9. Clinical Evidence: What the 2024–2026 Research Shows
10. Common Questions About the Adaptogen Definition
11. Summary: Putting the Adaptogen Definition Into Practice

---

Introduction

The word adaptogen gets used loosely. You will see it on supplement labels, wellness blogs, and pharmacy shelves attached to dozens of herbs, mushrooms, and botanical extracts. But behind the marketing language sits a precise scientific framework — one that has been refined over seven decades of pharmacological research and continues to be updated in peer-reviewed literature as recently as 2025 and 2026.

This post is not about trends. It is about understanding the adaptogen definition at the level the research actually uses: what the criteria are, where they came from, how regulatory bodies interpret them, and which substances genuinely satisfy all the conditions. By the end, you will be able to look at any substance marketed as an adaptogen and apply the same framework that clinical scientists use.

---

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

What Is an Adaptogen? The Core Concept Explained

If you have been asking what is adaptogen from a scientific standpoint rather than a wellness-marketing standpoint, the most honest starting point is this: an adaptogen is a pharmacological substance — almost always plant-derived — that increases the non-specific resistance of an organism to stress without causing more harm than the stressor itself.

The operative phrase is non-specific resistance. Unlike a drug that targets a single pathway (a beta-blocker lowering heart rate, for instance, or an antibiotic targeting a specific bacterial enzyme), an adaptogen is supposed to act broadly across biological stress-response systems. It is meant to help the organism cope with stressors of different kinds — physical, chemical, biological, and psychological — rather than intervening in one narrow mechanism.

The second essential quality is that the adaptation is normalizing. An adaptogen should bring dysregulated systems back toward baseline, regardless of which direction the dysregulation is running. If a marker is elevated under stress, an adaptogen should help lower it; if a marker is suppressed, it should help restore it. This bidirectional quality is what distinguishes the adaptogen concept from most conventional pharmacological categories.

The third quality, historically speaking, is that the substance must be essentially innocuous at normal doses — meaning it must not cause significant side effects or disturb normal physiological function even with repeated use.

These three qualities — non-specific action, normalizing effect, and innocuousness — form the original scientific tripod on which the adaptogen concept rests. They have been restated, refined, and contested across seven decades of research, but they remain the baseline framework in current reviews and regulatory discussions.

The History of the Adaptogen Concept: Brekhman's Framework

To understand the modern adaptogen concept, you need to go back to the Soviet Union in the late 1940s and 1950s. The term itself was coined by the Soviet pharmacologist Nikolai Lazarev in 1947. Lazarev was working on substances that could increase an organism's resistance to adverse influences in a general, non-specific way. He called this state of elevated non-specific resistance SNIR (State of Non-Specifically Increased Resistance), and he was looking for substances that could reliably induce it.

The term adaptogen appeared in Lazarev's work to describe a substance that could generate this state. But it was his student and colleague, Israel Brekhman, who transformed the concept from a loose pharmacological hypothesis into a defined scientific category — and adaptogen Brekhman is the pairing you will see cited in virtually every serious review of this field.

What Brekhman Actually Proposed

Working at the Institute of Biologically Active Substances in Vladivostok through the 1960s and 1970s, Brekhman — along with Dardymov — formalized the criteria for what qualified as an adaptogen. Their landmark papers established that to meet the definition, a substance had to satisfy three explicit conditions:

1. It must be innocuous and cause minimal disruption to normal physiological function.
2. It must have non-specific activity, meaning it must increase resistance to adverse influences of a wide range — physical, chemical, or biological.
3. It must have a normalizing influence on the organism, regardless of the direction of the pathological state.

These criteria were not arbitrary. They were designed to distinguish adaptogens from stimulants (which increase performance but often at a cost, and which do not normalize), from tonics (which have more general but less precise applications), and from immunomodulators (which act primarily on immune pathways rather than systemic stress response).

Brekhman's primary research subject was Eleutherococcus senticosus (Siberian ginseng), which he investigated as a potential safer alternative to Panax ginseng. His research program was partly motivated by practical Soviet-era goals: enhancing the performance and resilience of soldiers, cosmonauts, athletes, and industrial workers under high-demand conditions.

Why Brekhman's Framework Still Matters

You might expect that a framework developed in 1960s Soviet pharmacology would have been substantially revised or discarded by now. In fact, the opposite is true. A 2025 PMC review titled "Two Sides of the Same Coin for Health: Adaptogenic..." reiterates the core definition and criteria that trace directly back to Brekhman's formulation. A 2020 clinician-perspective paper restates the traditional three criteria — non-specific resistance, normalizing influence, and innocuousness — essentially unchanged from Brekhman's original language.

The framework has been extended and challenged but not replaced. The extensions have largely involved adding mechanistic detail — identifying specific molecular mediators like cortisol, HSP70, neuropeptide Y, nitric oxide, and AMPK pathways — that explain how adaptogens produce non-specific stress resistance at a cellular and systems level. But the three-part definitional structure remains intact.

The Three Scientific Criteria Every Adaptogen Must Meet

Let us now work through the adaptogen criteria in precise detail, because this is where most popular descriptions fall short.

Criterion 1: Innocuousness (Non-Toxicity at Effective Doses)

The first criterion is that an adaptogen must be essentially non-toxic when used at doses that produce the desired effect. This does not mean an adaptogen has zero risk at any dose — almost no substance in pharmacology is completely free of dose-dependent risk. What it means is that the margin between an effective dose and a harmful dose must be wide, and that at effective doses, the substance should not cause significant disruption to normal physiological function.

The European Medicines Agency (EMA) reflection paper on adaptogens phrases this as the substance being "almost non-toxic." This qualifier is important. It acknowledges that absolute non-toxicity is a pharmacological impossibility, while setting a standard that excludes substances with narrow therapeutic windows or significant side-effect profiles.

This criterion is one of the most frequently violated by substances informally labeled as adaptogens. Some herbs marketed as adaptogens have documented hepatotoxicity concerns, narrow dosing windows, or significant drug interactions that would disqualify them under strict application of this criterion.

Criterion 2: Non-Specific Activity (Broad Stress Resistance)

The second criterion is that the substance must increase resistance to stressors of multiple different types — not just one specific stressor. The original Brekhman framework included physical stressors (cold, heat, exercise, hypoxia), chemical stressors (toxic compounds, alcohol), and biological stressors (infection, radiation effects).

More recent framings have extended this to include psychological and cognitive stressors — work-related stress, sleep deprivation, examination pressure, and similar demands. The key is that the resistance should be general rather than specific to one type of challenge.

This criterion separates adaptogens from, say, a substance that only supports healthy cortisol in response to psychological stress but has no effect on physical stressors, or one that only increases endurance in hypoxic conditions but has no effect on inflammatory stress markers.

From a mechanistic standpoint, current research suggests that this non-specific quality is likely related to the action of adaptogens on core stress-response systems — particularly the hypothalamic-pituitary-adrenal (HPA) axis, the sympathoadrenal system, and downstream mediators including heat shock proteins, nitric oxide synthesis, and cortisol regulation — systems that are relevant to all categories of stressor, not just one.

Criterion 3: Normalizing Influence (Bidirectional Regulation)

The third criterion is arguably the most conceptually distinctive. An adaptogen must have a normalizing effect on the organism — meaning it should restore or maintain homeostasis rather than simply pushing a physiological marker in one direction.

To use a concrete example: a substance that only supports healthy cortisol would be an anti-stress agent but not strictly an adaptogen. A substance that supports healthy cortisol when cortisol is elevated and also supports cortisol output when it is abnormally suppressed (as in states of burnout or adrenal fatigue) would be meeting the normalizing criterion more faithfully.

The EMA reflection paper states explicitly that the effects of adaptogens should be more pronounced when pathological deviation is greater. In other words, a healthy person with normal cortisol levels and good stress resilience should experience less dramatic effects from an adaptogen than a stressed, depleted, or dysregulated person. This dose-response relationship with the degree of pathology is a distinctive feature of the adaptogen category.

This normalizing criterion is also why adaptogens are sometimes described as having homeostatic rather than pharmacological effects in the traditional sense. Rather than adding a fixed increment to a biological marker, they appear to modulate toward an optimal range.

Adaptogen Scientific Definition: How It Reads in the Literature

Having covered the three criteria in depth, it is worth examining how the adaptogen scientific definition actually appears in published clinical and pharmacological literature, because the exact wording matters.

The Classic Formulation

The most widely cited version of the adaptogen definition in the academic literature synthesizes Lazarev and Brekhman's work into something close to the following:

An adaptogen is a pharmacological substance of natural origin that is innocuous, produces a non-specific response that increases resistance to stress from physical, chemical, and biological factors, and has a normalizing influence on pathological conditions regardless of the direction of the disturbance.

Variations on this definition appear across dozens of review papers. The 2025 PMC review and the 2020 clinician-perspective paper both use formulations that map almost exactly to this structure, indicating that despite decades of additional mechanistic research, the core definition has not been substantially revised.

Additions Made by More Recent Research

While the three-part definitional structure has remained stable, more recent literature has added important clarifications:

Molecular mechanisms are now considered part of the definition context. The 2026 PubMed review covering seven major botanicals emphasizes that to be scientifically credible as an adaptogen, a substance should have identified cellular and molecular mechanisms explaining how it produces non-specific stress resistance. Mechanisms commonly cited include HPA axis modulation, HSP70 induction, AMPK pathway activation, and regulation of cortisol, neuropeptide Y, and nitric oxide — though no single mechanism is considered definitionally required.

The normalizing criterion has been operationalized more precisely. Modern research increasingly interprets "normalizing" in terms of specific biomarker outcomes — studies now measure effects on cortisol awakening response, salivary alpha-amylase, perceived stress scales, fatigue indexes, and cognitive performance under stress conditions. This gives the normalizing criterion more empirical traction than it had in Brekhman's original formulation.

The concept of "stress-protective" activity is now sometimes used alongside or in place of "non-specific resistance." Some researchers prefer this terminology because it is more directly testable in clinical trial designs. However, the traditional framework remains the reference standard in most systematic reviews.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Adaptogen Classification: How Researchers Categorize These Substances

Adaptogen classification is not as straightforward as it might seem. Different researchers and regulatory bodies use different categorical schemes, and there is no single globally agreed-upon taxonomy. However, several useful classification frameworks have emerged from the research literature.

Classification by Evidence Level

One practical approach to adaptogen classification is based on the strength of clinical evidence:

Well-characterized adaptogens with substantial human clinical evidence:

• Rhodiola rosea — multiple double-blind RCTs for fatigue, stress, and cognitive performance
• Withania somnifera (Ashwagandha) — a large body of RCT data for stress, cortisol, and fatigue
• Eleutherococcus senticosus — historically studied in Soviet research; less robust by modern RCT standards but with significant mechanistic data
• Panax ginseng — extensive research across cognitive, physical, and metabolic outcomes

Traditionally classified adaptogens with emerging but less complete clinical evidence:

• Schisandra chinensis
• Ocimum tenuiflorum (Holy Basil / Tulsi)
• Bacopa monnieri

This stratification is implicit in the 2026 systematic review that specifically focused on Withania somnifera and Rhodiola rosea as the most studied adaptogens for physical and psychological stress resilience — suggesting that even within the adaptogen category, there is significant variation in evidential support.

Classification by Primary Mechanism

Researchers also classify adaptogens by their primary mechanistic targets, though most adaptogens act through multiple overlapping pathways:

HPA axis modulators: Ashwagandha and rhodiola both have well-documented effects on cortisol regulation and HPA axis function.

CNS stress-response modulators: Rhodiola and eleutherococcus have been specifically studied for effects on central nervous system stress pathways, including serotonin, dopamine, and catecholamine systems.

Immune-neuroendocrine interface modulators: Schisandra and ginseng have documented effects at the intersection of immune and neuroendocrine stress responses.

Cellular stress-response inducers: Several adaptogens, including rhodiola and schisandra, have demonstrated induction of HSP70 (heat shock protein 70), which is a molecular marker of cellular stress resistance.

Classification by Traditional System of Origin

A third common classification approach distinguishes adaptogens by their traditional medicinal origins:

• Ayurvedic adaptogens: Ashwagandha, Bacopa monnieri, Holy Basil (Tulsi)
• Traditional Chinese Medicine adaptogens: Schisandra chinensis, Panax ginseng, Astragalus
• Northern/boreal adaptogens: Rhodiola rosea, Eleutherococcus senticosus, Aralia mandshurica
• African adaptogens (sometimes included): Sutherlandia frutescens, though this category is less established in Western clinical literature

It is worth noting that traditional classification and scientific classification do not always align. Some substances with long traditional use do not meet all three scientific criteria, and some substances with good scientific evidence have limited or inconsistent traditional use histories.

The Adaptogen Category in Regulatory and Official Contexts

One of the most common questions about the adaptogen official definition concerns whether it has any regulatory standing — and the answer is: partially yes, but with significant variation across jurisdictions.

The EMA Reflection Paper

The most rigorous official engagement with the adaptogen definition from a regulatory body comes from the European Medicines Agency. The EMA has produced a reflection paper on adaptogens that represents the most detailed attempt by a major regulatory body to operationalize the adaptogen concept for medicinal product assessment.

The EMA reflection paper explicitly states that:

• Adaptogens should be "almost non-toxic" at effective doses
• They should have non-specific effects that increase resistance to stress across organ systems
• Their normalizing effects should be more pronounced when pathological deviation is greater

This reflection paper is significant because it moves the adaptogen definition from the domain of academic pharmacology into the domain of regulatory medicine — giving it official definitional weight, at least for the purpose of EMA assessments of traditional herbal medicinal products.

The United States: No Formal Official Category

In the United States, the FDA does not recognize "adaptogen" as an official drug or supplement category. Substances marketed as adaptogens are generally regulated as dietary supplements under DSHEA (Dietary Supplement Health and Education Act) if they meet the definition of a dietary supplement, but the term "adaptogen" itself carries no regulatory standing. Companies can use the word on labels, but they cannot make specific medical claims about disease treatment.

This creates a notable gap between the scientific precision of the adaptogen definition and its regulatory status in the world's largest supplement market. Consumers in the United States have no regulatory framework to verify whether a product marketed as an adaptogen actually meets the scientific criteria.

Traditional Medicine Frameworks

In Russia and some Commonwealth of Independent States countries, adaptogens have a longer history of official pharmacological recognition, partly because the foundational research (Lazarev, Brekhman) was conducted within Soviet state institutions and was incorporated into Soviet pharmacological standards. Several adaptogenic preparations — including eleutherococcus extract — appeared in official Soviet pharmacopoeias.

In India, several Ayurvedic herbs now classified as adaptogens (ashwagandha, tulsi, bacopa) are regulated under the traditional Ayurvedic medicine framework through AYUSH (Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy), though this framework does not specifically use the term "adaptogen" in its classification logic.

Which Herbs Actually Meet the Adaptogen Requirements?

Now that the adaptogen requirements are clearly defined, we can apply them systematically to commonly discussed botanical candidates. This is an exercise that fewer popular sources take the time to do, and it produces some surprising results.

Rhodiola rosea — Meets All Three Criteria

Rhodiola rosea is currently among the best-documented adaptogens by modern RCT standards. The 2026 systematic review identified it as one of the most studied adaptogens for resilience to both physical and psychological stress. It meets the innocuousness criterion (a favorable safety profile with well-tolerated doses in the 200–600 mg standardized extract range), the non-specific resistance criterion (studies cover fatigue, cognitive stress, physical endurance, and burnout), and the normalizing criterion (bidirectional effects on cortisol and stress biomarkers have been documented).

Key active constituents include rosavin, salidroside, and tyrosol, with salidroside increasingly studied as a primary mediator of cellular stress protection.

Withania somnifera (Ashwagandha) — Meets All Three Criteria

Ashwagandha has accumulated the largest body of RCT evidence of any adaptogen candidate over the past decade. The 2026 systematic review placed it alongside rhodiola as one of the two most clinically substantiated adaptogens for stress resilience. Across multiple RCTs, ashwagandha has demonstrated significant reductions in perceived stress scores, cortisol levels, and measures of anxiety and fatigue. It meets the innocuousness criterion at studied doses (300–600 mg of root extract), the non-specific criterion (studied across psychological stress, physical performance, thyroid function, and sexual health outcomes), and the normalizing criterion (cortisol normalization rather than simply suppression).

Primary bioactive constituents are withanolides, with withaferin A receiving particular mechanistic attention.

Eleutherococcus senticosus (Siberian Ginseng) — Historically Meets All Three Criteria

Eleutherococcus has the longest formal adaptogen research history, as it was Brekhman's primary research subject. Its evidence base is extensive in quantity but older in methodology — much of the supporting data comes from Soviet-era studies that would not meet current RCT standards. Contemporary studies are fewer. It meets all three criteria conceptually and historically, and the safety profile is well-established, but it occupies a weaker evidentiary position by modern clinical standards than ashwagandha or rhodiola.

Panax ginseng — Meets Criteria With Qualifications

Panax ginseng has a very large research literature and a long safety record. It meets the innocuousness criterion (though with more noted interaction potential than rhodiola or ashwagandha), the non-specific criterion (studied across cognitive, metabolic, immune, and physical domains), and the normalizing criterion (ginsenosides have demonstrated bidirectional effects on immune and endocrine markers). The qualification is that high-dose ginseng use over extended periods has been associated with some side effects (insomnia, hypertension, hormonal effects) that slightly complicate the innocuousness criterion compared to other adaptogens.

Schisandra chinensis — Meets Criteria With Emerging Evidence

Schisandra is included in the 2026 review of seven major botanicals for stress-related mechanisms. It meets all three criteria theoretically and has good preclinical data, with a growing but still limited body of human clinical evidence. Its hepatoprotective effects are particularly well-characterized, and it has documented effects on physical endurance and mental performance under stress. The evidence base is sufficient to classify it as an adaptogen but less complete than the top tier.

Bacopa monnieri and Ocimum tenuiflorum — Partially Meet Criteria

Both are included in the 2026 review and have traditional adaptogen status in Ayurvedic medicine. Both have documented stress-modulating effects and favorable safety profiles. Bacopa monnieri has a particularly strong evidence base for cognitive outcomes but less clear non-specific stress resistance evidence across multiple stressor types. Ocimum tenuiflorum (holy basil) has strong preclinical data and some human evidence for cortisol reduction and stress response, but the clinical evidence base is thinner than the top-tier adaptogens.

What Gets Excluded?

Applying the criteria rigorously would exclude several substances frequently marketed as adaptogens:

• Maca (Lepidium meyenii) — more correctly classified as a nutritional adaptogen with limited evidence for non-specific stress resistance by the strict criteria
• Licorice root at high doses — potential for mineralocorticoid effects that compromise the innocuousness criterion
• Gotu kola — primarily a nervine tonic; limited evidence for non-specific stress resistance across multiple stressor types
• Reishi and lion's mane mushrooms — often labeled as adaptogens but more accurately classified as immunomodulators or nootropics respectively; limited evidence for the specific normalizing and non-specific resistance criteria

How Adaptogens Differ From Stimulants and Nootropics

This comparison is important for understanding the precise edges of the adaptogen category.

Adaptogens vs. Stimulants

The distinction Brekhman drew between adaptogens and stimulants is one of his most important conceptual contributions. A stimulant — caffeine being the obvious example — increases arousal and performance acutely, but it does so by essentially borrowing from future reserves. It pushes biological systems harder rather than increasing their capacity or resilience. When the stimulant wears off, there is typically a rebound effect — fatigue is delayed, not eliminated.

An adaptogen, according to the definitional criteria, should not produce this stimulant-rebound pattern. Its effects should not be accompanied by increased arousal per se, but rather by increased capacity to handle demands without the same degree of biological disruption. Adaptogens are also supposed to work over time with continued use, building resilience, rather than producing acute performance spikes that diminish with tolerance.

The practical distinction: rhodiola taken before a stressful period should not give you a caffeine-like buzz but should allow you to handle the stress with less cortisol dysregulation and faster recovery. The absence of the stimulant-rebound cycle is partly what makes the innocuousness criterion achievable.

Some adaptogens — rhodiola in particular — do have mild stimulating-adjacent effects, which has led to occasional misclassification, but the mechanism and the response profile are pharmacologically distinct from classic stimulants.

Adaptogens vs. Nootropics

The nootropic category is even broader and less rigorously defined than the adaptogen category, which is saying something. A nootropic (from the Greek nous + tropos: mind-turning) is loosely defined as any substance that enhances cognitive function. The definition formulated by Corneliu Giurgea in 1972 proposed five criteria, but these have not been consistently applied, and the term is now used colloquially to describe almost any supplement with cognitive claims.

An adaptogen is not necessarily a nootropic, and a nootropic is not necessarily an adaptogen. Panax ginseng and Bacopa monnieri have substantial evidence for both categories. Rhodiola rosea has cognitive evidence but primarily in the context of stress-induced cognitive impairment, which aligns with the normalizing criterion of the adaptogen definition. Racetams, often called nootropics, have no stress-response or normalizing mechanism and would not meet adaptogen criteria.

The practical distinction: adaptogens work through stress-response and homeostatic mechanisms; nootropics may work through any cognitive enhancement pathway including neurotransmitter modulation, cerebral blood flow, or neuroplasticity enhancement, without necessarily addressing stress physiology.

Clinical Evidence: What the 2024–2026 Research Shows

The most recent research continues to both validate and refine the adaptogen concept at a clinical level.

2025 PMC Review: Restating the Core Framework

The 2025 PMC review "Two Sides of the Same Coin for Health: Adaptogenic..." is notable because, despite being a recent publication with access to decades of accumulated mechanistic data, it reiterates the classical three-part definition framework. This is significant — it suggests that the scientific community has not found cause to fundamentally revise the Brekhman criteria even as molecular mechanisms have been identified. The review represents a validation of the definitional stability of the adaptogen concept.

2026 Systematic Review: Ashwagandha and Rhodiola

The 2026 PubMed systematic review focusing on Withania somnifera and Rhodiola rosea specifically examined clinical evidence for adaptogenic effects on resilience to physical and psychological stress. The fact that these two herbs were singled out for systematic review treatment — rather than the broader seven-herb grouping — suggests that the clinical evidence community recognizes a tier of adaptogens with sufficient RCT data to support formal systematic analysis.

This review effectively confirmed what several meta-analyses had suggested over the prior decade: that ashwagandha and rhodiola have the most methodologically robust human trial evidence for adaptogenic effects in the clinical sense.

2026 Molecular Mechanisms Review: Seven Botanicals

The 2026 review titled "System-Level, Molecular and Cellular Mechanisms of Selected Plant..." covered Rhodiola rosea, Schisandra chinensis, Withania somnifera, Eleutherococcus senticosus, Panax ginseng, Ocimum tenuiflorum, and Bacopa monnieri. This review represents the most comprehensive recent attempt to map the molecular mechanisms underlying adaptogenic effects across the most studied botanicals.

Key findings from this mechanistic literature include:

• HPA axis modulation remains the most consistently documented mechanism across adaptogens, with effects on cortisol, ACTH, and CRH documented for ashwagandha, rhodiola, and eleutherococcus.

• HSP70 induction (heat shock protein 70, a key cellular stress-resistance protein) has been demonstrated for rhodiola and schisandra particularly, providing a molecular basis for the "non-specific resistance" criterion.

• AMPK pathway activation has been identified as a mechanism for several adaptogens, connecting to both energy regulation and cellular stress response.

• Neuropeptide Y and galanin regulation have been proposed as CNS-level mechanisms, particularly relevant to the psychological stress resilience effects of adaptogens like rhodiola.

EMA Framework Updates (2025–2026)

The continued citation of EMA reflection paper standards in 2025–2026 literature confirms that the EMA's three-part criteria framework (near-non-toxicity, non-specific stress resistance, normalizing action with greater effects under greater pathological deviation) remains the reference standard for official regulatory contexts.

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Common Questions About the Adaptogen Definition

Q: What exactly is an adaptogen in scientific terms?

An adaptogen is a natural pharmacological substance — almost always plant-derived — that meets three criteria: it must be essentially non-toxic (innocuous) at effective doses, it must produce non-specific resistance to stressors of multiple types, and it must have a normalizing influence on biological systems regardless of the direction of dysregulation. This definition traces to Lazarev (1947) and was formalized by Brekhman and Dardymov in the 1960s–1970s.

Q: Which scientific criteria must a substance meet to be called an adaptogen?

The three criteria are: (1) innocuousness / near-non-toxicity at effective doses, (2) non-specific stress resistance across physical, chemical, biological, and psychological stressors, and (3) normalizing action that restores homeostasis bidirectionally regardless of which direction pathology is running. These are the same criteria referenced in the 2025 PMC review and the EMA reflection paper.

Q: Are adaptogens officially recognized in medicine or regulation?

Partially. The EMA (European Medicines Agency) has produced a reflection paper that gives the adaptogen definition official regulatory standing in the EU context. In Russia, several adaptogens appeared in Soviet pharmacopoeias. In the United States, the FDA does not recognize "adaptogen" as a formal drug or supplement category.

Q: Which herbs are considered true adaptogens under the scientific definition?

The herbs most consistently meeting all three criteria with the strongest clinical evidence are: Rhodiola rosea, Withania somnifera (ashwagandha), and Eleutherococcus senticosus. Panax ginseng and Schisandra chinensis also meet the criteria with somewhat greater methodological caveats. Bacopa monnieri and Ocimum tenuiflorum partially meet the criteria, with ongoing evidence accumulation.

Q: What clinical evidence supports adaptogens for stress, fatigue, or cognition?

The strongest evidence is for ashwagandha and rhodiola, identified in a 2026 systematic review as the most clinically documented adaptogens for physical and psychological stress resilience. Both have multiple RCTs showing effects on cortisol, perceived stress scores, fatigue, and cognitive performance under stress conditions.

Q: How are adaptogens different from stimulants?

Stimulants increase arousal and performance acutely by pushing biological systems harder, typically with rebound fatigue. Adaptogens are defined in part by not following this pattern — they should increase the biological capacity to handle stress without the stimulant-rebound cycle, and their innocuousness criterion is partly what separates them from stimulants.

Q: Are adaptogens safe for long-term use?

The innocuousness criterion is definitionally part of being an adaptogen, so a substance with significant long-term safety concerns arguably does not qualify under strict criteria. For the well-characterized adaptogens (rhodiola, ashwagandha, eleutherococcus), long-term use at studied doses appears to be well-tolerated, but research on very long-term use (>12 months) in clinical populations remains limited.

Q: Which adaptogens have the best human evidence?

By current RCT standards: Withania somnifera (ashwagandha) and Rhodiola rosea have the most robust human clinical evidence. They were specifically selected for systematic review treatment in the 2026 literature on this basis.

Summary: Putting the Adaptogen Definition Into Practice

The adaptogen definition has remained surprisingly stable across seven decades — a testament to how carefully Brekhman and his colleagues constructed the original criteria. Three conditions define the category: innocuousness, non-specific stress resistance, and normalizing action. These criteria are not just historical artifacts; they are restated in 2025 PMC reviews, operationalized in EMA regulatory documents, and used as the evaluative framework in 2026 systematic reviews.

The adaptogen concept is precise in its scientific application, even if the popular use of the word has become imprecise. When you encounter the term on a supplement label, in a wellness article, or in a clinical protocol, the question to ask is: does this substance have evidence of near-non-toxicity at effective doses? Does it have evidence of non-specific resistance across multiple stressor types? Does it have evidence of normalizing, bidirectional effects on relevant biomarkers?

Applying those three questions rigorously, the list of botanicals that genuinely deserve the designation is shorter than the marketing landscape suggests — but the substances that do qualify represent a genuinely interesting and clinically meaningful pharmacological category with growing evidentiary support.

The adaptogen category sits at an interesting intersection of traditional medicine and modern pharmacology. The herbs that occupy the highest evidence tier — ashwagandha and rhodiola — have both long traditional use histories and now substantial RCT evidence. The molecular mechanisms being identified in 2025–2026 research are providing increasingly sophisticated explanations for effects that traditional practitioners observed centuries ago.

This convergence of traditional knowledge and modern evidence — grounded in a precise scientific definition — is what makes the adaptogen concept worth taking seriously, both clinically and for anyone with a serious interest in stress physiology and resilience.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

References and Source Notes

All factual claims in this article are grounded in the following sources and research:

• Brekhman II, Dardymov IV. New substances of plant origin which increase non-specific resistance. Annu Rev Pharmacol. 1969.
• PMC review: Two Sides of the Same Coin for Health: Adaptogenic... PMC12472958. Published 2025.
• PMC review: Effects of Adaptogens on the Central Nervous System and the Molecular Mechanisms... PMC3991026.
• PMC review: Evolution of the adaptogenic concept from traditional use to... PMC7756641. Published 2020.
• 2026 PubMed systematic review: Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea.
• 2026 PubMed review: System-Level, Molecular and Cellular Mechanisms of Selected Plant Adaptogens.
• EMA Reflection Paper on adaptogens (cited as reference [14] in the indexed literature above).
• 2020 clinician-perspective paper restating traditional three criteria (cited as reference [6]).

This article is for informational and educational purposes. It does not constitute medical advice. Consult a qualified healthcare provider before making changes to your supplement or medication regimen.